Polyrizon (PLRZ) stock underwent a massive rally on Tuesday after the biotech company announced an update on its manufacturing upscaling endeavors. The company said it has reached a new milestone for the production of its proprietary nasal-spray product platform. It said this will support its clinical and regulatory activities while also preparing it for a future commercial launch.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
According to Polyrizon, the company and its manufacturing partner made the transition from batch laboratory production to a large-scale controlled manufacturing run for the company’s PL-14 formulation. This shows the reliability of PL-14 in large-batch creation and will be used for the company’s clinical trial that is expected to start in 2026.
Tomer Izraeli, CEO of Polyrizon, said, “The process validated our manufacturing strategy. With this batch in hand, we are energized and prepared to advance into next batches toward clinical trial material manufacturing, which we believe brings us one step closer to addressing the unmet needs in the nasal spray market.”
Polyrizon Stock Rallies on Manufacturing Update
Polyrizon stock was up 114.87% in pre-market trading on Tuesday, following a 1.56% drop yesterday. The shares have decreased 99.9% year-to-date and 99.82% over the past 12 months.
Today’s manufacturing update triggered heavy trading of PLRZ stock, as some 42 million shares changed hands this morning. For comparison, the company’s three-month daily average trading volume is about 42,000 units.
With an upcoming clinical trial, today’s rally could be the start of a turnaround for Polyrizon stock. However, traders will also want to be wary of the extreme gains the stock has seen today, which could be due to hype from retail traders and not long-term investors.
